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SUMMARY 
The role of the sympathetic nervous system, stress, and hypertension in metabolic 
syndrome and obesity remains unclear. To clarify this issue, we utilized genetically 
engineered mice showing chronic sympathoexcitation and hypertension due to lack of 
Vav3, a Rac1 activator. Here, we report that these animals develop metabolic 
syndrome under chow diet. However, they show protection from metabolic syndrome 
and obesity under fatty diets. These effects are elicited by α1 adrenergic- and diet-
dependent metabolic changes in liver and the α1/β3 adrenergic-mediated stimulation 
of brown adipocyte thermogenesis. These responses seem to be engaged by the local 
action of noradrenaline in target tissues rather than by long-rage effects of adrenaline. 
By contrast, they are not triggered by low parasympathetic drive or the hypertensive 
state present in Vav3-deficient mice.  These results indicate that the sympathetic 
system plays divergent roles in the etiology of metabolic diseases depending on food 
regimen, sympathoexcitation source, and disease stage. 
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INTRODUCTION 
Metabolic syndrome (MS) encompasses a complex array of dysfunctions such as type 2 
diabetes, liver steatosis, dyslipemia, pan-inflammatory conditions and hypertension often, 
but not always, linked to obesity (Moller and Kaufman, 2005).  This condition has become 
pandemic in recent years due to increased sedentary and high calorie diet lifestyles in both 
developing and industrialized societies (Hossain et al., 2007).  It is therefore important to 
understand the physiological and metabolic mechanisms affecting the origin and 
progression of this complex disease. 
One of the main mechanisms to buffer energy surpluses induced by high calorie 
intake is to engage energy-consuming anabolic and catabolic programs in the white (WAT) 
and brown adipose tissue (BAT), respectively. The WAT consumes energy by synthesizing 
and storing triglycerides. The BAT dissipates energy as heat using a thermogenic, 
mitochondrial-based program (Cannon and Nedergaard, 2004).  These two activities are 
coordinated by the sympathetic nervous system (SNS) via the local release of noradrenaline 
(also known as norepinephrine) in WAT and BAT. This catecholamine promotes WAT 
lipolysis as well as BAT recruitment and BAT lipolysis/thermogenesis (Cannon and 
Nedergaard, 2004; Robidoux et al., 2004).  In some conditions, the SNS can trigger further 
thermogenesis via the generation, expansion, and stimulation of “brown-in-white” (brite) 
adipocytes in the WAT (Robidoux et al., 2004).  The SNS also controls basal metabolic 
rates and other diet-related processes (i.e., insulin secretion or glucose metabolism), thus 
ensuring the coordinated control of energy expenditure at the whole organism level 
(Lambert et al., 2010). Depending on the type of the physiological response involved, the 
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SNS can regulate the above processes by releasing noradrenaline from local fibers or, 
alternatively, using the adrenaline (also known as epinephrine) secreted by the adrenal 
gland medulla (Lambert et al., 2010). The integration of metabolic parameters and SNS 
activation takes place primarily in different areas of the central nervous system that 
coordinate food intake and body weight.  Those regions, in turn, receive signals from tissue 
afferents, adipose tissue-generated adipokines, thyroid hormones, and metabolites (Morton 
et al., 2006). 
In addition to the disruption of adipose tissue-dependent responses during MS and 
obesity, it has been postulated that the development of some of those diseases can originate 
as a consequence of sustained activation of the SNS.  In favor of this view, some 
epidemiological studies have shown that individuals affected of sympathetic-driven chronic 
stress, tachycardia, or borderline hypertension have higher tendencies to develop MS-
related diseases and obesity (Lambert et al., 2010; Mancia et al., 2007; Pervanidou and 
Chrousos, 2012).  Conversely, some studies have linked obesity-induced SNS activity with 
increased tendencies to develop other comorbidities such as hypertension and 
atherosclerosis (Lambert et al., 2010; Mancia et al., 2007).  However, it is worth noting the 
existence of quite a few contradictory clinical reports on all those issues so, at this moment, 
this is still an open area of debate (Lambert et al., 2010; Mancia et al., 2007).   
To dissect the role of the SNS in MS ontogeny in a genetically clean manner, we 
decided to use in this work a knockout mouse strain for Vav3, a gene that encodes a Rho 
GDP/GTP exchange factor (Rho GEF) involved in the upstream activation of the Rac1 
subfamily of Rho GTPases (Movilla and Bustelo, 1999).  These animals display chronic 
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sympathoexcitation due to axon migration/guidance defects that disrupt the GABAergic 
wiring that connects the caudal (CVLM) with the rostral ventrolateral medulla (RVLM) in 
the brainstem. As a consequence, these animals develop RVLM- and SNS-associated 
dysfunctions such as tachycardia, tachypnea, hypertension, and other hypertension-related 
dysfunctions (Guyenet, 2006; Sauzeau et al., 2010a; Sauzeau et al., 2006).  Thus, we 
believed that this mutant mouse strain could represent an ideal tool to investigate the effect 
of sustained SNS hyperactivity and the VLM itself on both diet-induced physiological 
responses and the etiology of MS and obesity. 
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RESULTS 
Vav3 deficient mice develop liver steatosis and type 2 diabetes under chow diet 
conditions 
Given the general effects of the SNS in energy balance and basal metabolism (Lambert et 
al., 2010), we decided to investigate whether Vav3–/– mice had defects in any of those 
parameters under chow diet conditions.  We did not find any difference between Vav3–/– 
and control mice in body weight (Fig. S1A-C), percentages of fat/lean mass (Fig. S1B,C), 
cumulative food intake (Fig. S1D), circadian VO2/VCO2 quotients (Fig. S1E) or overall 
energy expenditure (Fig. S1F).  These mice did show a slight reduction in locomotor 
activity during the dark period (Fig. S1G), although such difference was not relevant when 
normalized according to their specific lean mass (Fig. S1G).  No variations in plasma levels 
of thyroid stimulating hormone, triiodothyronine (T3), and thyroxine (T4) were observed 
either (Fig. S1H-J). 
Further analyses revealed that Vav3–/– mice developed hepatic steatosis, as 
evidenced by the abnormal large size (Fig. 1A) and increased weight (Fig. 1B) of livers 
obtained from euthanized animals. Consistent with this, we also observed the characteristic 
presence of lipid-enriched hepatocytes (Fig. 1C,D) and high amounts of triglycerides (Fig. 
1E) in livers from Vav3–/– mice.  The fatty liver disease became visually and histologically 
detectable in 4 month-old mice and, since then, underwent a progressive worsening until 
reaching a non-alcoholic fatty liver or steatohepatitic state in ≈90% of 1 year-old mice (Fig. 
1C,D).  Alterations in liver function were indirectly confirmed by the detection of elevated 
concentrations of triglycerides (Fig. 1F) and liver dysfunction markers such γ-glutamyl 
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transpeptidase (GGT, Fig. 1G) and bilirubin (Fig. 1H) in the plasma of Vav3–/– mice. The 
hypertriglyceridemia ran in parallel with the time in which the physical/histological signs of 
liver steatosis were detected (Fig. 1F). However, γ-glutamyl transpeptidase and bilirubin 
were already upregulated in 2 month-old mice (Fig. 1G,H), indicating that liver 
dysfunctions started earlier than the physical manifestations of steatosis in Vav3–/– mice.  
These mice also displayed typical signs of type 2 diabetes, including hyperglycemia 
(Fig 2A, compare values at time-point 0), decreased glucose tolerance (Fig. 2A,B) and 
hyperinsulinemia (Fig. 2C,D).  Impaired glucose tolerance was first detected in 2 month-
old animals and remained a stable parameter through the life of Vav3-deficient mice (Fig. 
2B). The basal hyperinsulinemic state was also consistently detected from 3 to 12 month-
old animals (Fig. 2C).  This last defect was due to both increased pancreatic secretion (Fig. 
2E) and reduced clearance by liver (Fig. 2F).  The intravenous injection of insulin induced 
lower amounts of Akt phosphorylation in the liver (Fig. 2G) and less efficient glucose 
clearance rates from circulation (Fig. 2H) in Vav3–/– mice than in controls, further 
confirming that the loss of Vav3 induced type 2 diabetes in mice. qRT-PCR analyses 
indicated that these physiological changes correlated with progressive, time-dependent 
changes in the expression of transcripts associated with the development of a post-receptor 
insulin resistance state (Fig. S2A).  The first change observed was the upregulation of the 
Ppargc1a mRNA in 1.5 month-old mice (Fig. S2B-C). This transcript encodes Pgc1α, a 
cAMP-induced transcriptional cofactor involved in glucagon-mediated fasting responses 
such as gluconeogenesis, fatty acid oxidation and ketogenesis. It also favors insulin 
resistance by inhibiting Akt in a TRB3-dependent manner (Fig. S2A) (Fernandez-Marcos 
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and Auwerx, 2011).  mRNAs for transcriptional factors involved in de novo lipogenesis and 
fatty liver disease (Srebp1) were first seen upregulated in 2.5 month-old mice (Fig. S2A,C-
D) (Shao and Espenshade, 2012). By contrast, transcripts for Pparα and Insig2 became only 
upregulated in 3.5 month-old mice (Fig. S2A-D). Pparα is a transcriptional factor that 
cooperates with Pgc1α in some signaling responses, including the induction of insulin 
resistance in a TRB3-dependent manner (Fig. S2A) (Kersten et al., 2000). Insig2 is a 
negative regulator of Srebp1 positively and negatively regulated by Pparα and the 
insulin/PI3K/Akt route, respectively (Fig. S2A) (Dong and Tang, 2010).  All those mRNAs 
were detected upregulated in 6 month-old Vav3–/– mice (see below, Fig. S6). Despite this 
steatotic state, these mice did not develop typical peripheral dysfunctions associated to 
post-receptor insulin resistance such as adipocyte hypertrophy or obesity (Fig. S1B,C; see 
also Fig. 3C below) (Brown and Goldstein, 2008).  
To rule out the possibility that this phenotype was induced by the hypertensive state 
of Vav3–/– mice, we performed similar analyses in mice deficient for a second member of 
the Vav family, Vav2.  This mutant strain shows angiotensin II-dependent hypertension and 
high plasma catecholamine levels. However, unlike Vav3–/– mice, the upregulation of 
plasma catecholamines is angiotensin II-dependent in this case and, therefore, is located 
downstream rather than upstream of the hypertensive condition (Sauzeau et al., 2010b). We 
did not find any sign of liver steatosis (Fig. 2I,J), hyperinsulinemia (Fig. 2K), 
hyperglycemia (Fig. 2L) or impaired glucose tolerance (Fig. 2L) in these mice, indicating 
that hypertension-mediated effects are not the direct cause of the MS present in Vav3–/– 
mice. 
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The Vav3 deficiency protects mice from high fat diet-induced obesity 
We next investigated whether the administration of a high fat diet (HFD) could aggravate 
the fatty liver disease and insulin resistance of Vav3–/– mice. To that end, we fed cohorts of 
2 month-old mice with a HFD for a 10 month-long period.  Unlike wild type animals, we 
observed that HFD-fed Vav3-deficient mice gained less weight (Figs. 3A and S3A), had 
smaller fat deposits (Figs. 3B and S3A) and did not develop white adipocyte hypertrophy 
(Fig. 3C,D). Against our initial expectations, we also found that the HFD seemed to exert 
beneficial actions on Vav3–/– animals, since the abnormal increases in the weight and 
triglyceride content of livers previously found in chow diet-fed Vav3–/– mice were reduced 
by the HFD administration (Fig. 3E-H).  Moreover, livers from HFD-fed mutant mice 
maintained the high abundance of the Ppargc1a mRNA but, instead, did not show the 
upregulation of Srebp1c, Ppara or Insig2 transcripts when compared to HFD-fed controls 
(Fig. 3I).  Consistent with the lack of steatosis, this tissue also showed low abundance of 
the mRNA encoding fatty acid synthase (Fasn) (Fig. 3I), an enzyme essential for lipid 
biosynthesis.  HFD-fed Vav3–/– mice showed glucose tolerance (Figs. 3J), insulin 
sensitivity (Fig. 3K) and plasma insulin levels (Fig. 3L) similar to those found in chow 
diet-fed wild type mice, further indicating that the Vav3 deficiency affects obesity and MS-
like dysfunctions in a diet type-dependent manner. 
 
Vav3-deficient mice show enhanced BAT thermogenesis 
The resistance to HFD-induced obesity of Vav3–/– mice was not due to changes in food 
intake (Fig. S3B), circadian VO2/VCO2 quotients (Fig. S3C), overall energy expenditure 
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(Fig. S3D,E), or the plasma concentration of the thyroid-derived T3 (1.08 ± 0.06 vs. 1.02 ± 
0.08 ng/ml in controls) and T4 (3.52 ± 0.19 vs. 2.77 ± 0.26 ng/ml in controls; n = 5 
mice/genotype) hormones.  However, they showed increased levels of energy 
expenditure/lean mass (Fig. S3E, right panel) and locomotor activity during the light period 
(Fig. S3F).  Further analyses indicated that they also displayed higher intrascapular surface 
(Fig. 4A,B) and rectal (37.9 ± 0.1 ºC vs 37.1 ± 0.2 ºC of controls; P ≤ 0.009, n = 7) 
temperature when compared to controls.  This was associated to the activation of a BAT 
thermogenic program, as evidenced by the consistent, age-independent upregulation of the 
Ucp1 mRNA in BAT samples from Vav3–/– mice (Fig. 4C-F).  Ucp1 is a BAT-specific 
protein that uncouples oxidative phosphorylation from the respiratory chain, leading to 
energy dissipation as heat (Cannon and Nedergaard, 2004).  The increase in the abundance 
of this transcript in both 2.5 and 3.5 month-old mice took place in parallel to the induction 
of Pgc1α (Fig. 4E,F), the transcriptional factor involved in the transcriptional activation of 
the Ucp1 gene during the thermogenic response (Cannon and Nedergaard, 2004).  
However, the Ppargc1a mRNA was not upregulated in the BAT of 0.5 and 1.5 month-old 
mice (Fig. 4C,D), suggesting that other transcriptional factors were in charge of that role 
during those early postnatal periods.  qRT-PCR analyses indicated that Krüppel-like factor 
15 (Klf15) was the most likely candidate to functionally replace Pgc1α in the BAT of 
young mice (Fig. S4A-D).  Although the thermogenic response is usually associated with a 
decrease in fat vesicles present in brown adipocytes and a concomitant reduction in cell 
size, histological analyses revealed that the BAT from 1 and 6 month-old Vav3–/– mice was 
composed of cells harboring very large lipid vesicles that were more hypertrophic than 
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those present in wild type BAT samples (Fig. 4G).  As a result, we observed consistent 
lower cell densities in the BAT of Vav3–/– mice than in control animals in most ages tested 
(Fig. 4H).  This may reflect different differentiation degrees of brown adipocytes in control 
and mutant mice or, alternatively, that the lipolysis associated with the thermogenic 
program is compensated in standard diet-fed Vav3–/– mice by the uptake of lipids from other 
tissues such as the liver or WAT.  This cytological pattern changed upon HFD 
administration.  Thus, this diet induced the accumulation of large lipid vacuoles in brown 
adipocytes (Fig. 4I) and a concomitant decrease in BAT cell density (Fig. 4J) in the case of 
wild type mice.  By contrast, it promoted a reduction in lipid stores (Fig. 4I) and an 
increase in BAT cell density (Fig. 4J) in the case of Vav3–/– mice. Taken together, these 
observations indicate that the lack of obesity development in HFD-fed Vav3–/– mice is 
related to increased levels of both energy consumption/lean mass and BAT thermogenesis. 
This latter program is active even under standard diet and environmental temperature 
conditions. 
 
Vav3-deficient mice show enhanced white-to-brown transdifferentiation 
qRT-PCR analyses revealed that the Ucp1 mRNA expression was also upregulated in WAT 
samples obtained from Vav3–/– mice (Fig. S4E-I).  Such increase (8-9 fold) was in fact 
significantly higher than that seen in BAT of same animals (2-3 fold) (compare Figs. 4C-F 
and S4G-I).  However, it developed at later times than in the case of BAT (compare Figs. 
4C-F and S4E-I). Unlike the case of BAT, the WAT samples from Vav3–/– mice also 
displayed the parallel upregulation of Ucp3 transcripts (Fig. S4G-H).  The transcripts for 
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Pgc1α and some of its co-transcriptional partners (Pparα, Pparγ) were also elevated in 
WAT samples from 4.5 month-old Vav3–/– mice but not in those from younger animals 
(Fig. S4E-I), suggesting the implication of other transcriptional factors in the activation of 
the Ucp1 gene in young Vav3–/– mice. Since Ucp1 gene expression is limited to brown 
lineage cells (Cannon and Nedergaard, 2004), these results indicate the presence of ectopic 
thermogenesis in WAT via the generation and expansion of brite cells. 
 
The thermogenesis of Vav3 deficient mice is sympathetic-dependent 
To investigate if the thermogenesis found in Vav3–/– mice was sympathetic-dependent, we 
subjected control and mutant animals to treatments with a number of adrenergic 
antagonists.  The administration of the SR59230A, a β3 receptor inhibitor, promoted the 
rapid drop in the abundance of the Ucp1 mRNA in the BAT of Vav3–/– mice that, under 
those conditions, reached values similar to those present in untreated control mice (Fig. 
5A). SR59230A had no effects on the abundance of the Ucp1 transcript in the BAT of wild 
type mice (Fig. 5A).  The administration of the generic β1/β2 adrenergic inhibitor 
propranolol did not have any effect in BAT Ucp1 mRNA levels in Vav3–/– mice (Fig. 5A). 
Doxazosin (an α1 adrenergic receptor antagonist) promoted the short-term upregulation of 
the Ucp1 mRNA content in the BAT of those mice (Fig. 5A).  In agreement with those 
results, we observed that the administration of SR59230A also eliminated the hyperthermia 
of Vav3–/– mice whereas the same dose elicited no effect on the basal temperature of control 
animals (Fig. 5B,C).  These results indicate that chow diet-fed Vav3–/– mice activate BAT 
thermogenesis in a sympathetic-dependent manner and, in addition, that such activation 
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utilizes the classical pro-thermogenic noradrenaline/β3 adrenergic receptor route present in 
brown and brite adipocytes. 
 
Vav3–/– mice show abnormal regulation of SNS activity during both chow and high fat 
diet conditions 
We previously reported that the sympathoexcitation of Vav3 null mice, measured indirectly 
as increased plasma levels of catecholamines, is detected in newborns and remains rather 
stable up to at least a year of age under standard chow diet conditions. This dysfunction 
precedes the angiotensin II-dependent hypertension and cardiovascular remodeling that 
takes place in these animals (Sauzeau et al., 2006).  To investigate the evolution of SNS 
activity in HFD-fed animals, we monitored periodically the plasma concentration of those 
two catecholamines in mice subjected to a HFD since they were 2 month-old.  As control, 
we maintained parallel groups of animals under chow diet.  As expected (Sauzeau et al., 
2006), Vav3–/– mice displayed higher plasma concentrations of noradrenaline (Fig. 5D) and 
adrenaline (Fig. 5E) than controls during all the experimental period under chow diet 
conditions.  The HFD conditions had no influence on plasma noradrenaline during the first 
month of diet change in Vav3–/– mice but, since then, promoted a progressive reduction in 
the concentration of this catecholamine that, at the latest experimental time point, reached 
levels similar to those shown by chow diet-fed control mice (Fig. 5D).  HFD-fed wild type 
mice displayed a transient, 3-fold increase on the plasma concentration of noradrenaline 
one month upon the diet change and, since that time-point on, maintained 2 fold higher 
amounts of plasma noradrenaline than when kept under chow diet (Fig. 5E).  The HFD 
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conditions induced a further, although slight increase of the plasma concentration of 
adrenaline in Vav3–/– mice upon the change into HFD (Fig. 5E).  However, unlike the case 
of noradrenaline, the plasma levels of adrenaline remained at high levels during the rest of 
the experiment conducted with Vav3 deficient mice (Fig. 5E).  The HFD promoted a 
progressive elevation of the plasma concentration of adrenaline in wild type mice, with a 
maximum peak reached four months after the diet change (Fig. 5E). These results indicate 
that the sympathoexcitation of Vav3–/– mice is present both in chow diet and during early 
HFD periods. Furthermore, they show that the overall noradrenergic, but not the adrenergic 
drive of these animals is inhibited upon the long-term administration of HFD. 
Since the parasympathetic nervous system (PNS) plays roles in general metabolic 
regulation and liver glucose metabolism (Marino et al., 2011), we also analyzed the status 
of this branch of the autonomic system in both control and mutant mice.  We observed that 
chow diet-fed Vav3–/– mice had a lower PNS tone, as evidenced by the lower plasma 
amount of choline, one of the degradation products of acetylcholine (Fig. S5A).  Consistent 
with this, we found that Vav3–/– mice also displayed delayed PNS-dependent 
gastrointestinal responses when compared to controls (Fig. S5B,C). Similar results were 
found in Vav2–/– mice (Fig. S5D), suggesting that the reduction of parasympathetic activity 
per se is not inextricably linked to the development of metabolic defects in mice.  The 
overall PNS activity was reduced under HFD conditions in control and, to a much larger 
extent, in Vav3–/– mice (Fig. S5E).  This result rules out the possibility that the elimination 
of the MS-like phenotype in HFD-fed Vav3–/– mice could be due to a 
restoration/exacerbation of PNS tone.  To further assess the potential contribution of lower 
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PNS tone in the liver to the metabolic defects exhibited by Vav3–/– mice, we performed 
hepatic vagotomies to investigate the effects induced by the entire PNS denervation of liver 
on chow diet-fed wild type mice.  When compared to sham-operated mice, vagotomized 
mice exhibited normal parameters for overall autonomic activity (Fig. S5F-H), 
cardiovascular and breathing rates (Fig. S5I,-K), liver structure (Fig. S5L,M), plasma 
concentration of hepatic markers (Fig. S5N-P) and glucose metabolism (Fig. S5Q-S). Thus, 
in the absence of sympathoexcitation, the reduction of parasympathetic signals to the liver 
does not reproduce the dysfunctions seen in chow diet-fed Vav3–/– mice.  Further analyses 
indicated that vagotomized mice did not have active thermogenic programs in the BAT 
(Fig. S5T) and WAT (Fig. S5U), ruling out the possibility that the activation of those 
processes in Vav3–/– mice could be indirectly derived from the elimination of vagally 
transmitted afferent signals from the liver. 
 
The thermogenesis and hypertension of Vav3–/– mice show similar upstream, 
sympathetic-dependent co-regulation 
We have previously shown that the stereotaxic administration of a GABAA receptor 
antagonist (bicuculline) into the RVLM of wild type mice phenocopies the Vav3 gene 
deficiency in terms of induction of high plasma catecholamine levels, tachypnea, 
tachycardia, and hypertension in mice.  By contrast, this drug has a minor impact on Vav3–/– 
mice since they have already lost the tonic inhibitory control regulated by presynaptic 
GABAergic neurons present in the RVLM (Sauzeau et al., 2010a).  During these 
experiments, we observed that bicuculline induced the same aforementioned effects when 
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administered intravenously at low doses to mice (see below).  We used this strategy to 
investigate whether the hyperthermia and hypertension were subjected to similar upstream 
controls by the SNS in chow diet-fed Vav3–/– mice.  We found that bicuculline induced a 
sharp and rapid elevation of plasma catecholamines (Fig. 5F,G), blood pressure (Fig. 5H), 
and BAT Ucp1 mRNA levels (Fig. 5I) when administered to wild type mice. The latter 
effect could be blocked by the SR59230A β3 receptor antagonist, further confirming that 
bicuculline induced the Ucp1 transcript in wild type brown adipocytes in a noradrenaline/β3 
receptor-dependent manner (Fig. 5I).  However, and similar to the marginal effect on the 
elevation of both plasma catecholamine (Fig. 5F,G), and blood pressure levels (Fig. 5H), 
bicuculline had no detectable impact on the abundance of the BAT Ucp1 transcript when 
injected into Vav3–/– mice (Fig. 5I).  As a control, the administration of noradrenaline 
induced similar increases in blood pressure in wild type and Vav3–/– mice (Fig. 5H).  The 
administration of bicuculline had no effect in the plasma levels of choline in both wild type 
and mutant mice (Fig. 5J), indicating that the short-term systemic administration of this 
drug only had an effect in the sympathetic branch of the autonomic nervous.  These results 
indicate that the hypertension and BAT hyperthermia present in Vav3–/– mice are both 
associated to dysfunctions in the tonic control of the SNS by inhibitory GABAergic signals. 
 
α1 adrenergic receptor antagonists block the metabolic dysfunctions present in chow- 
and HFD-fed Vav3–/– mice 
The results presented in the previous sections did not give any hint about the potential 
implication of the SNS in the liver steatosis and type 2 diabetes exhibited by Vav3–/– mice 
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under chow diet conditions.  To tackle this issue, we decided to investigate the effect of the 
systemic administration of α1 (doxazosin) and β1/β2 (propranolol) adrenergic receptor 
antagonists in chow diet-fed Vav3–/– and wild type mice.  We chose those inhibitors because 
α1 and β2 adrenergic receptors play major roles in metabolic regulation in liver, skeletal 
muscle and other tissues, including brain (Lambert et al., 2010).  To that end, we started the 
administration of adrenergic receptor antagonists in chow diet-fed 1 month-old animals and 
evaluated results five month later under the same diet conditions (Fig. 6A). To get further 
information about the effect of adrenergic receptor inhibitors on the metabolic phenotype of 
Vav3–/– mice, we also decided to monitor the effect on such treatments in animals that were 
fed under HFD for the last four months of the experiment (Fig 6A).  We found that the 
long-term application of either doxazosin or propranolol had no effects on the overall 
weight (Fig. 6B) and WAT content (data now shown) of chow diet-fed Vav3–/– mice.  
However, doxazosin, but not propranolol, prevented the development of hepatic steatosis in 
chow diet-fed mutant mice, as demonstrated by the wild type-like size (Fig. 6C,D), 
histology (Fig. 6E) and triglyceride content (Fig. 6F) of their livers (for a summary of these 
results, see Fig. S6A).  Interestingly, these treatments affected differentially the transcripts 
previously found upregulated in the liver of Vav3–/– mice.  Thus, doxazosin eliminated the 
upregulation of Ppargc1a, Srebp1a and Srebp1c mRNAs (Figs. S6B) whereas propranolol  
only affected the expression of the Ppargc1a transcript (Fig. S6B).  The overexpression of 
Insig2 and Ppara mRNAs was not eliminated by any of those drugs (Fig. S6B), suggesting 
that they were not regulated by SNS signals. Consistent with the acquisition of normal 
metabolic responses, we observed that the long-term doxazosin treatment blocked the 
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development of the hyperinsulemic (Fig. 6G) and the glucose intolerance (Fig. 6H) states 
present in Vav3–/– mice animals (Fig. S6A).  Unlike the case of the short-term experiments 
(see above, Fig. S5A), doxazosin also eliminated the thermogenic program previously 
observed in the BAT, as demonstrated by the reduced abundance of Ppargc1a and Ucp1 
mRNAs in the BAT of Vav3–/– mice (Fig. S6C,D).  Propranolol treatments did not eliminate 
any of those dysfunctions (Fig. 6G-H and S6A,C). 
Under HFD conditions, doxazosin abrogated the protective effect of the Vav3 
deficiency on weight gain (Fig. 6B), WAT expansion (Fig. 6I), white adipocyte 
hyperplasia (Fig. 6J), obesity-induced liver steatosis (Fig. 6C-E), and obesity-triggered 
glucose intolerance (Figs. 6H and S6A).  It also eliminated the thermogenic programs in 
the BAT (Fig. 6K and S6D) and WAT (Fig. S6E) of Vav3–/– mice.  These results indicate 
that the chronic stimulation of α1 adrenergic receptors contributes to the development of 
MS in chow-fed Vav3–/– mice and, in combination with β3 adrenergic receptors, to the anti-
obesity and anti-MS effects of the Vav3 deficiency in HFD-fed mice (Fig. S6A,F). By 
contrast, β1/β2 adrenergic receptor-dependent mechanisms did not seem to contribute to any 
of the above processes, since parallel propranolol treatments did not induce any detectable 
effect on the metabolic phenotype of both chow and HFD-fed Vav3–/– mice (Fig. S6A,F). 
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DISCUSSION 
This work has revealed that chow diet-fed Vav3–/– mice develop an “incomplete” post-
receptor insulin state characterized by typical liver and plasma MS-like pathophysiologies 
that, unexpectedly, is not associated to other defects such as white adipocyte hypertrophy 
and obesity (Brown and Goldstein, 2008).  Interestingly, these mice do not develop those 
dysfunctions when maintained under long-term HFD conditions and, in addition, show a 
marked protection from the obesity and MS usually elicited by that food regimen.  Our 
results indicate that several SNS-dependent processes contribute to the development of this 
metabolic phenotype.  The lack of increased adiposity and obesity observed in these 
animals under both diet conditions can be explained by the SNS-mediated activation of 
thermogenic programs in the BAT and, subsequently, in WAT.  Notably, these programs 
are activated independently of the dietary (HFD) or environmental (i.e., cold exposure) 
conditions that normally trigger them under physiological conditions.  The cause of the 
diet-dependent diabetes and steatosis of these animals remains to be fully explained from a 
mechanistic point of view. However, an integrated analysis of the pathophysiological and 
molecular changes exhibited by these mice suggests that it may entail both liver 
autonomous (diet-independent) and non-autonomous (diet-dependent) alterations.  
Consistent with the presence of intrinsic signaling events in the liver, we have observed that 
the SNS-dependent upregulation of the Ppargc1a mRNA in this tissue takes place 
independently of the diet type and pathophysiological status of Vav3–/– mice (Fig. S6F). By 
contrast, the expression of the Srebp1, Ppara and Insig2 mRNAs is highly dependent on 
the diet type and presence of active thermogenic programs (Fig. S6F). The regulation of 
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these transcripts is also heterogeneous, since their expression is SNS-dependent (Srebp1) 
and independent (Ppara, Insig2) (Fig. 6F).  These results indicate that this latter expression 
program is controlled by signaling events extrinsic to the liver.  The WAT and BAT are 
likely candidates to trigger those non-autonomous responses, as evidenced by the 
correlation observed between the doxazosin-mediated inactivation of thermogenic 
programs in those tissues and the elimination of the protection offered by the Vav3 
deficiency against HFD-induced obesity and MS (Fig. S6A).  Given the drastic anti-
diabetic and steatotic effects induced by minor variations in the activity of lipolytic and 
fatty acid oxidation routes in adipocytes (Girousse et al., 2013; Waki et al., 2007), it is 
possible that such influence could be mediated by diet-dependent changes in the flux of free 
fatty acids and triglycerides between them and the liver.  Consistent with this, we have 
observed significant changes in the histology and abundance of Pargc1a and Ucp1 mRNAs 
in the BAT depending on the diet type (Figs. 4 and S6D). Other possibilities include HFD-
dependent changes in adrenergic drive among different tissues and/or the activation of 
neuroendocrine afferent/efferent-based loops affecting liver metabolic output.  More work 
will be required to fully understand this process. 
We have shown that Vav3–/– mice develop SNS-dependent dysfunctions due to the 
loss of tonic GABAergic inhibitory control of the RVLM (Sauzeau et al., 2010a; Sauzeau 
et al., 2006).  It is possible therefore that the metabolic defects reported here could have a 
similar etiology. The lack of feeding or thyroid hormone alterations in Vav3–/– mice also 
argues against a direct implication of sympathoregulatory areas of the brain associated to 
food intake and energy expenditure in this phenotype (Morton et al., 2006).  However, it is 
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worth noting that the BAT thermogenesis found in Vav3–/– mice is at odds with the known 
inhibitory effects of the RVLM in this process (Madden, 2011; Morrison, 1999).  This 
discrepancy can be taken as evidence for the presence of additional dysfunctions in other 
thermoregulatory centers in these mice such as, for example, the rostral raphe pallidus 
(rRPa) (Morrison et al., 2008).  Alternatively, it is possible that the disinhibited RVLM of 
Vav3–/– mice could induce rRPa-independent thermogenesis through the chronic stimulation 
of sympathetic fibers that innervate the intra-BAT vasculature. This is in agreement with 
observations showing that, under normothermia conditions, local sympathetic activity in 
the BAT correlates well with the activity level of RVLM-regulated functions such as heart 
rate and blood pressure (Morrison, 1999).  A similar explanation can be used for the 
stimulation of WAT thermogenesis and liver routes, since most of the catecholaminergic 
nerve terminals in these tissues are adjacent to blood vessels (Robidoux et al., 2004; Yi et 
al., 2010).  In any case, and given the multiple sympathoregulatory areas involved in 
metabolic regulation, we cannot formally exclude the possibility that the Vav3 deficiency 
could affect some of those areas in either RVLM-dependent or independent fashions.  If 
that were the case, our bicuculline experiments suggest that such role must be still linked to 
the proper wiring of inhibitory, GABAergic-dependent signals.  In the same context, is also 
possible that SNS-dependent metabolic defects could be further accentuated by the parallel 
reduction in PNS tone present in Vav3–/– mice. 
The increased levels of catecholamines in the plasma of Vav3–/– mice also raise the 
issue of whether their metabolic defects are induced through sympathetic efferents (using 
either direct innervations or local paracrine actions from catecholamine spill-over) and/or 
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long-range, adrenalin-mediated signals.  We currently favor the former possibility, since 
Vav2–/– mice show no metabolic defects despite displaying similar levels of plasma 
catecholamines (Sauzeau et al., 2007). Likewise, knock-in mice lacking Rac1 expression 
exclusively in vascular smooth muscle cells indicate that they do not develop diabetes or 
steatosis despite displaying a Vav2–/– cardiovascular phenotype and elevated, angiotensin II-
induced plasma levels of catecholamines (S.F, M.M-M. and XRB, unpublished 
observations).  We also have observed that the chronic infusion of catecholamines in wild 
type mice for 15 days using implanted drug-delivery pumps does not trigger the 
upregulation of the Ppargc1a mRNA in liver (data not shown).  Notwithstanding this 
evidence, it is quite possible that hormonal-based mechanism could participate in other 
metabolic programs not explored in this work.  For example, it is known that the RVLM 
reacts to glycoprivation by stimulating adrenaline secretion from the adrenal gland 
(Verberne and Sartor, 2010).  Further analyses of additional SNS-regulated metabolic 
responses will be important to identify the spectrum of pathophysiological defects present 
in these mice and the nervous/hormonal mechanisms involved in triggering them. 
There is a lot of debate about the implication of chronic sympathoexcitation and 
stress in the development of MS and obesity or on whether hypertension can favor insulin 
resistance and MS.  There are also conflicting reports on whether the obesity-induced SNS 
activity can drive or collaborate in the development of associated diseases such as 
hypertension or atherosclerosis (Lambert et al., 2010; Mancia et al., 2007; Pervanidou and 
Chrousos, 2012).  Solving these issues is important to understand whether those diseases 
are etiologically intertwined or, alternatively, whether they co-develop independently in 
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patients due to either dietary habits or lifestyle.  However, it has been rather difficult 
answering them at the clinical level given the multiple ethnic, gender, and environmental 
factors influencing the evolution of those diseases in humans (Lambert et al., 2010).  The 
sympathoexcitation present in Vav family mice has given us the opportunity to address 
some of those questions in a genetically and environmental “clean” manner.  Our results are 
consistent with the idea that chronic sympathoexcitation does promote the development of 
pathophysiological dysfunctions traditionally linked to MS. In this context, they also 
suggest that treatments with doxazosin, but not with β1/β2 blockers such as propranolol, 
could be beneficial to eliminate MS-related dysfunctions in the case of non-obese 
individuals with both MS and signs of high SNS activity (i.e., hypertension, tachycardia). 
Such benefit would represent a burden, however, in the case of obese individuals with 
increased SNS activity, since doxazosin will block the protective effect of chronic 
sympathoexcitation on obesity and obesity-induced MS. By contrast, our data are not 
consistent with an implication of chronic sympathoexcitation in the development of obesity 
regardless of the diet type used.  Our work also rules out any direct effects of hypertension 
per se on insulin resistance at the systemic level, because Vav2–/– mice do not display any 
overt signs of insulin resistance or steatosis despite exhibiting angiotensin II-dependent 
hypertension (Sauzeau et al., 2007). The results obtained with wild type mice do support 
the consensus idea that obesity does promote SNS activation.  However, the examination of 
that response during a 10 month-long period has revealed that such regulation is highly 
complex, since it involves the differential and time-dependent regulation of both 
sympathetic neurons and the adrenal gland medulla. 
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To our knowledge, this is the first demonstration of the implication of a Rho GEF in 
biological programs connected to the regulation of metabolic diseases.  However, our 
genome encodes more than 60 additional Rho GEFs (Bos et al., 2007), many of which are 
expressed in tissues involved in metabolic regulation such as the liver, adipose tissue, 
muscle or brain.  It is therefore quite important to conduct further genetic analyses with 
members or this enzyme family to identifying new therapeutically appealing targets for the 
treatment of MS, obesity, and associated diseases.  




Vav3–/– and Vav2–/–C57BL/10 mice (Doody et al., 2001; Sauzeau et al., 2006) were utilized 
according to protocols approved by the Bioethics committees of the University of 
Salamanca, CSIC, and University of Santiago de Compostela. Mice were kept in ventilated 
rooms in pathogen-free facilities under controlled temperature (23°C), humidity (50%) and 
illumination (12-hour light/12-hour dark cycle) conditions.  After weaning, mice were fed a 
standard chow global diet #2918 (6.2% fat, 3.1 kcal/g; Harlan). When indicated, 2 month-
old mice were shifted to a HFD protocol (45% fat, 4.73 kcal/g; Research Diets).  
Experimental procedures made on these mice are described in the Supplemental Material 
file available online. 
 
Statistics 
Data were analyzed using one-way Anova test or Student’s t test for comparison between 
two unpaired groups. Values were considered significant when P ≤ 0.05.  In all figures, 
data values are given as mean ± standard error of the mean (SEM).  
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FIGURE LEGENDS 
FIGURE 1. Vav3–/– mice develop steatosis. (A,B) Representative images (A) and evolution 
of weight (B) of livers isolated from chow diet-fed mice of the indicated genotypes and 
ages. *, P ≤ 0.05 relative to same-age controls (n = 5). In panel A and in rest of figures, all 
images of whole livers were taken using the same magnification. (C) Representative 
images of histological sections obtained from livers of mice of indicated genotypes and 
ages. Scale bar, 100 µm. (D) Anatomopathology of livers from mice of indicated genotypes 
and ages (left). The x/y ratio represent the number of animals (x) showing a given 
phenotype within the total number of animals (y) analyzed.  Values diverging between 
control and mutant mice are shown in red color. NAFL, non-alcoholic fatty liver; NASH, 
non-alcoholic steatohepatitis. (E) Triglyceride content of livers from 4 month-old mice of 
indicated genotypes. *, P ≤ 0.05 (n = 6). WT, wild type mice; KO, Vav3–/– mice. (F-H) 
Plasma concentrations of triglycerides (F), γ-glutamyl transpeptidase (GGT) (G) and 
bilirubin (H) in mice of the indicated genotypes and ages. *, P ≤ 0.05 relative to values 
obtained at the same time-point with controls (n = 4-5).  Error bars in panels of this figure 
represent the SEM. See also Fig. S1. 
 
FIGURE 2. Chow diet-fed Vav3–/– mice develop type 2 diabetes. (A) Glucose tolerance test 
showing reduced glucose tolerance in chow diet-fed 4 month-old Vav3–/– mice. *, P ≤ 0.05 
relative to values obtained at the same time-point with controls (n = 5).  (B) “Area-under-
the-curve” (a.u.c.) values for the plasma concentration of glucose in mice of indicated 
genotypes and ages upon an injection of glucose. **, P ≤ 0.01; ***, P ≤ 0.001 relative to 
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same-age controls (n = 5). (C) Plasma insulin levels in mice of indicated genotypes and 
ages. *, P ≤ 0.05 relative to values obtained at the same time-point with controls (n = 4-6).  
(D) Evolution of insulin plasma levels upon an injection of glucose in 4 month-old mice of 
indicated genotypes. *, P ≤ 0.05 relative to values obtained at the same time-point with 
controls (n = 3-4). (E) Effect of glucose in insulin secretion (measured indirectly through 
the quantification of the plasma levels of the C-peptide proteolytic byproduct generated 
during insulin biosynthesis). *, P ≤ 0.05 relative to values obtained at the same time-point 
with controls (n = 4).  (F) Clearance rates of human insulin in control and Vav3 null mice. 
*, P ≤ 0.05 relative to values obtained at the same time-point with controls (n = 3-4). (G) 
Phosphorylation levels of Akt in indicated residues in the livers of mice of indicated 
genotypes that were either nontreated (–) or treated (+) with insulin.  The expression of α-
tubulin (bottom panel) was used as loading control.  (H) Evolution of the plasma 
concentration of glucose in 4 month-old mice of indicated genotypes upon an injection of 
insulin. *, P ≤ 0.05 relative to values obtained at the same time-point with controls (n = 5). 
(I) Liver weight of wild type (WT) and Vav2–/– (KO) mice (n = 5). (J) Representative 
images of livers (upper panels) and liver histological sections (lower panels) of mice from 
indicated genotypes. (K) Plasma insulin levels in mice of indicated genotypes (n = 5). (L) 
Evolution of the plasma concentration of glucose in mice of indicated genotypes during 
glucose tolerance tests (n = 5).  All data shown in panels I-L were obtained using 4 month-
old mice. Error bars in panels of this figure represent the SEM. See also Fig. S2. 
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FIGURE 3. Vav3–/– mice are resistant to obesity and MS under HFD conditions.  (A) 
Evolution of body weight in animals of the indicated genotypes subjected to HFD since 
they were 2 month-old. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to values obtained 
at the same time-point with controls (n = 5-6).  (B) Representative images of mice at the 6 
month time-point of the experiment shown in A. F, fat; L, liver. (C,D) Representative 
image of epigonadal WAT (C) and average size distribution of epigonadal white adipocytes 
(D) from 6 month-old mice of indicated genotypes that were kept under either chow or 
HFD conditions as in A. **, P ≤ 0.01 (n = 5).  (E,F) Representative image (E) and total 
weight (F) of livers extracted from 6 month-old mice of indicated genotypes previously 
kept under high fat (HFD) or chow diet (Chow) conditions for 4 months. *, P ≤ 0.05; ***, 
P ≤ 0.001 relative to chow diet-fed controls (n = 5).  (G) Representative image of 
hematoxylin-eosin (upper panels) and oil red-stained (lower panels, to visualize lipids) liver 
sections from 6 month-old mice of indicated genotypes after being maintained under HFD 
conditions for 4 months. Scale bar, 200 µm. (H) Triglyceride content of livers from 6 
month-old mice of indicated genotypes after being fed under either chow or HFDs 
conditions for 4 months. *, P ≤ 0.05; **, P ≤ 0.01 relative to chow diet-fed controls or 
indicated experimental pairs (in brackets) (n = 5). (I) Abundance of indicated transcripts in 
the liver of HFD-fed control and mutant mice. *, P ≤ 0.05; **, P ≤ 0.01 (n = 5). (J,K) 
Plasma concentration of glucose upon the injection of either glucose (I) or insulin (J) in 6 
month-old wild type and Vav3–/– mice previously subjected to HFD conditions during a 4 
month period. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to values obtained at the 
same time-points with controls (n = 5). (L) Plasma insulin levels present in overnight fasted 
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6-month-old mice of indicated genotypes and diet protocols. *, P ≤ 0.05 relative to chow 
diet-fed controls (n = 5). Error bars in panels of this figure represent the SEM. See also Fig. 
S3. 
 
FIGURE 4. Vav3–/– mice show enhanced BAT thermogenesis. (A,B) Representative 
thermal images (A) and body temperature recordings (B) of chow diet-fed mice of 
indicated genotypes and ages. ***, P ≤ 0.001 relative to same-age controls (n = 4-5).  (C-F) 
Abundance of indicated transcripts in the BAT of 0.5 (C), 1.5 (D), 2.5 (E) and 3.5 (F) 
month-old wild type and Vav3–/– mice maintained under chow diet conditions. Values 
obtained for each transcript in control mice were given an arbitrary value of 1. a.u., 
arbitrary units. *, P ≤ 0.05; **, P ≤ 0.01 (n = 3-4). (G) Representative images of BAT 
sections from chow diet-fed mice of indicated genotypes and ages.  Scale bar, 200 µm. (H) 
Number of brown adipocytes present in intercapsular BAT sections from chow diet-fed 
mice of the same age. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to same-age 
controls (n = 3-4). (I) Representative images of BAT sections from 6 month-old mice of 
indicated genotypes after being fed a chow or HFD for 4 months.  Scale bar, 200 µm. (J) 
BAT cell density in animals from the experiment in panel I. **, P ≤ 0.01; ***, P ≤ 0.001 
relative to chow diet-fed controls (n = 3-4). Error bars in panels of this figure represent the 
SEM. See also Fig. S4. 
 
FIGURE 5. BAT thermogenesis in Vav3–/– mice is sympathetic-dependent. (A) Relative 
abundance of the Ucp1 mRNA in the BAT of chow diet-fed animals of indicated genotypes 
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that were either non-treated (–) or treated with the SR59230A (SR), propranolol (Prop) and 
doxazosin (Doxa) inhibitors. **, P ≤ 0.01 (n = 5).  (B,C) Representative thermogram (B) 
and body temperatures (C) of chow diet-fed mice of indicated genotypes treated with either 
placebo (–) or SR59230A (+) for 24 hours. ***, P ≤ 0.001 (n = 4). (D,E) Plasma 
concentration of noradrenaline (D) and adrenaline (E) in chow and HFD-fed mice of 
indicated genotypes and ages. **, P ≤ 0.01; ***, P ≤ 0.001 relative to same-age controls (n 
= 5). (F-J) Effect of bicuculline on plasma catecholamines (F,G), blood pressure (H), BAT 
Ucp1 mRNA levels (I) and plasma choline (J) in chow diet-fed mice of indicated 
genotypes.  In H, animals were anesthetized and placed in a blood pressure recording 
equipment. **, P ≤ 0.01 (n = 5). Injection times are indicated by arrows. Scale bar, 1 min. 
Error bars in panels of this figure represent the SEM. See also Fig. S5. 
 
FIGURE 6. α1 adrenergic receptor antagonists block the metabolic dysfunctions present in 
chow- and HFD-fed Vav3–/– mice. (A) Scheme of these experiments. (B-F) Effect of 
doxazosin (Doxa) and propranolol (Prop) in both total body weight (B) and appearance (C), 
weight (D), histology (E), and triglyceride content (F) of livers of Vav3–/– mice fed under 
chow or HFD (HF) conditions. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to controls 
under the same diet type (n = 5). Scale bar in E, 200 µm. (G) Plasma levels of insulin in 
overnight fasted 6-month-old mice subjected to chow diet and treatments with adrenergic 
receptor antagonists as above. *, P ≤ 0.05 (n = 5). (H) a.u.c. values of the plasma 
concentration of glucose in 6-month-old mice of indicated genotypes and treatments upon 
using a glucose tolerance test. **, P ≤ 0.01; ***, P ≤ 0.001 relative to controls under the 
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same diet type (n = 5). (I) Representative images of HFD-fed 6 month-old mice of 
indicated genotypes and treatments. (J,K) Histological epigonadal WAT (J) and scapular 
BAT (K) sections from HFD-fed 6 month-old mice of indicated genotypes and treatments. 
Scale bar: 200 µm. Error bars in panels of this figure represent the SEM. See also Fig. S6. 
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Figure S1. Normal metabolic parameters in chow diet-fed Vav3–/– mice. Data related to 
Figure 1. (A) Evolution of whole body weight during the aging of mice of indicated 
genotypes (n = 8-9). (B) Representative images of a wild type and a Vav3–/– mouse showing 
no evidence of fat accumulation in the latter animals. (C) Body weight and fat/lean mass 
accumulation in chow diet-fed mice (2 month-old) of the indicated genotypes using 
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metabolic cage and NMR measurements, respectively (n = 8-9). WT, wild type mice; KO, 
Vav3–/– mice. (D) Food intake of control and Vav3 null 2 month-old mice during a 48 hour-
long period (n = 8-9).  (E) Respiratory quotient (RQ) was estimated and represented as 
light phase RQ (left panel), dark phase RQ (middle panel) and total RQ (right panel) (n = 8-
9).  (F) Energy expenditure of 2 month-old mice of indicated genotypes shown as: (i) 
Overall expenditure during a 48 hour-long period (left panel). (ii) Expenditure during the 
dark and light periods (middle panel; black and open boxes, respectively).  (iii) Expenditure 
normalized according to percentage of lean mass (right panel) (n = 8-9). (G) Locomotor 
activity during dark and light periods (left panel, black and open boxes, respectively) and 
normalized according to lean mass (right panel) of indicated mouse cohorts (2 month-old).  
*, P ≤ 0.05 relative to values obtained in control mice (n = 8-9). (H-J) Concentration of 
thyroid stimulating hormone (H), T3 (I) and T4 (J) in the blood of chow diet-fed 4 month-
old mice of indicated genotypes (n = 8). Error bars in panels of this figure represent the 
SEM. 
Menacho-Márquez et al. (2013) 
 4 
 
Figure S2. Deregulated expression of genes in livers of chow-fed Vav3–/– mice. Data 
related to Figure 2. (A) Scheme of pathways involved in type 2 diabetes of the post-
receptor insulin resistance type. Routes involved in gluconeogenesis, de novo lipogenesis 
and fatty acid oxidation/ketogenesis are shown in green, blue and red, respectively.  Grey 
elements connect the gluconeogenic and lipogenic routes at either the signaling or 
transcriptional level.  Activation and inactivation steps are indicated by arrows and blunted 
lanes, respectively. In most cases of type 2 diabetes (referred to as post-receptor insulin 
resistance), insulin fails to inhibit the PI3K/Akt route, leading to the inability to block 
gluconeogenesis and ensuing hyperglycemia. By contrast, the receptor is still capable of 
activating the lipogenic route, leading to hypertriglyceridemia. The two routes are only 
efficiently inactivated when the insulin receptor is not functional, such as the case of 
LIRKO mice (Brown and Goldstein, 2008; Koo et al., 2004; Laplante and Sabatini, 2010; 
Semple et al., 2009).  FoxO1, forkhead box protein O1; IRS, insulin receptor substrate; 
Menacho-Márquez et al. (2013) 
 5 
mTORC1, mammalian target of rapamycin complex 1; PI3K, phosphatidylinositol 3-
kinase; PKC, protein kinase C; Pgc1α, peroxisome proliferator-activated receptor gamma, 
coactivator 1 α; Pparα, peroxisome proliferator-activated receptor α; TRB3, tribbles 
homolog 3. (B-D) Abundance of indicated transcripts in livers of 1.5 (B), 2.5 (C), and 3.5 
(D) month-old wild type and Vav3–/– mice maintained under chow diet conditions.  Values 
obtained for each transcript in control samples were given an arbitrary value of 1.  a.u., 
arbitrary units.  *, P ≤ 0.05; **, P ≤ 0.01 relative to values obtained in control samples of 
the same age (n = 4). Srebp1a and Srebp1b are two differentially spliced forms of the 
primary transcript. Srebf1 refers to the simultaneous amplification of transcripts for those 
two isoforms. Error bars in panels of this figure represent the SEM. 
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Figure S3. Metabolic parameters of Vav3 deficient mice under HFD conditions. Data 
related to Figure 3.  (A) Body weight and fat/lean mass accumulation in HFD-fed mice of 
the indicated genotypes using metabolic cage and NMR measurements, respectively. *, P ≤ 
0.05 (n = 8). (B) Food intake of control and Vav3 null mice during a 48 hour-long period (n 
= 8).  (C) Respiratory quotient (RQ) was estimated and represented as light phase RQ (left 
panel), dark phase RQ (middle panel) and total RQ (right panel) (n = 8).  (D) Real time 
energy expenditure recordings of indicated mouse cohorts (n = 8). (E) Average energy 
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expenditure according to lean mass (left and right panel) and dark/light cycles (middle 
panel; black and open boxes, respectively. *, P ≤ 0.05 (n = 8). (F) Locomotor activity 
distributed in dark (closed boxes) and light (open boxes) periods and according to lean 
mass in HFD-fed mice of indicated genotypes. *, P ≤ 0.05 (n = 8).  In all these experiments, 
5 month-old mice that were kept for 3 months under HFD were used. Error bars in panels 
of this figure represent the SEM. 
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Figure S4. Age-dependent expression of mRNAs in adipose tissues of Vav3–/– mice. Data 
related to Figure 4. (A-D) Abundance of indicated transcripts in the BAT of 0.5 (A), 1.5 
(B), 2.5 (C) and 3.5 month-old (D) wild type and Vav3–/– mice maintained under chow diet 
conditions. Values obtained for each transcript in control samples were given an arbitrary 
value of 1. **, P ≤ 0.01 relative to the appropriate control sample (n = 3-4). (E-I) 
Abundance of indicated transcripts in the WAT of 0.5 (E), 1.5 (F), 2.5 (G), 3.5 (H) and 4.5 
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(I) month-old wild type and Vav3–/– mice maintained under chow diet conditions. *, P ≤ 
0.05; **, P ≤ 0.01 relative to values obtained in control samples of the same age (n = 3-4). 
Error bars in panels of this figure represent the SEM. 




Figure S5. Lack of contribution of the parasympathetic system to the phenotype of Vav3–/– 
mice. Data related to Figure 5. (A) Amount of plasma choline in animals of indicated 
genotypes and ages *, P ≤ 0.05; **, P ≤ 0.01 relative to values obtained in control samples 
of the same age (n = 4).  (B,C) Gastric emptying rates (B) and intraintestinal food transit 
time (C) in 2 month-old mice of indicated genotypes. *, P ≤ 0.05; ***, P ≤ 0.001  relative 
to values obtained in control samples (n = 5).  (D) Amount of plasma choline in 2 month-
old control and Vav2–/– mice. **, P ≤ 0.01 relative to values obtained in controls (n = X). 
(F-H) Plasma concentration of noradrenaline (F), adrenaline (G) and choline (H) in 4 
month-old wild type mice that were subjected to either a sham (S) or a hepatic vagotomy 
(V) 1.5 months before euthanasia (n = 5).  (I-K) Mean arterial pressure (I), heart rates (J) 
and mean breathing frequency (K) of wild type mice that were subjected to either a sham or 
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hepatic vagotomy as in panels F-H (n = 5). (L,M) Example of the histology (L) and weight 
(M) of livers obtained from indicated sham and vagotomized mice (n = 5). (N-P) Plasma 
concentrations of bilirubin (N), triglycerides (O) and GGT (P) in sham-operated and 
vagotomized mice (n = 5). (Q,R) Example of a glucose tolerance test (Q) and “Area-under-
the-curve” (a.u.c.) values (R) for the plasma concentration of glucose in sham-operated and 
vagotomized mice upon an injection of glucose (n = 5). (S) Plasma insulin levels in sham-
operated and vagotomized animals (n = 4). (T,U) Abundance of indicated mRNAs in the 
BAT (T) and WAT (U) of sham-operated and vagotomized wild type mice. Values 
obtained for each transcript in control samples were given an arbitrary value of 1 (n = 3). 
Error bars in panels of this figure represent the SEM. 




Figure S6. Effect of a systemic inhibition of the sympathetic nervous system in the 
metabolic phenotype of Vav3–/– mice.  Data related to Figure 6. (A) Summary of results 
described in Figure 6. The presence or elimination of an abnormal dysfunction is 
highlighted with red and blue colors, respectively.  In MS-like, we include all the biological 
parameters related to the metabolic syndrome condition (liver steatosis, glucose tolerance, 
etc.).  (B-E) Abundance of indicated mRNAs in the liver (B), BAT (C,D) and WAT (E) of 
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chow diet- (B-D) and HFD-fed (D,E) 6 month-old mice of indicated genotypes that were 
either non-treated or treated with adrenergic receptor antagonists for 5 months. Values 
obtained for each transcript in control samples were given an arbitrary value of 1. *, P ≤ 
0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to values obtained in control samples or 
indicated experimental pairs (brackets) (n = 3). (F) Expression patterns of indicated 
mRNAs (left) in liver, BAT and WAT of Vav3–/– mice under the indicated experimental 
conditions (data derived from experiments shown in Figures S2B-D, 3I, 4C-F, S4 and 
S6B-E).  Age of animals is indicated at the top.  The initiation and duration of the HFD and 
drug treatments is indicated by red and blue arrows, respectively.  The upregulation of a 
given transcript under chow and HFD conditions is indicated by light brown and blue lanes, 
respectively.  Dashed lanes indicate periods analyzed that showed no statistically 
significant variations of a given transcript when compared to samples from control mice. 
The functional substitution of the Ppargc1a by the Klf15 mRNA in the BAT of young mice 
is indicated by a gray lane. The inhibition (arrowhead) o no effect (–) of doxasozin and 
propranolol treatments is indicated on the right.  The color indicates whether the effect of 
the treatment was analyzed in chow diet-fed mice (light gray, liver), in HFD-fed mice 
(black) or in both chow diet- and HFD-fed animals (dark gray, BAT). Error bars in panels 
of this figure represent the SEM. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
In vivo determination of metabolic parameters 
Whole body composition was measured using NMR imaging (Whole Body Composition 
Analyzer; EchoMRI).  Animals were monitored in a custom 12-cage indirect calorimetry, 
food intake and locomotor activity monitoring system (TSE LabMaser, TSE Systems) as 
described (Nogueiras et al., 2007). Mice were acclimated for 48 hours to the test chambers 
and then monitored for an additional 48 hour-long period. Data collected form the last 48 
hours were used to calculate all parameters shown in this work.  Body core temperature was 
measured using a digital thermometer (Ved Beep-Grandate CO, Italy).  Heat production 
was also visualized using a high-resolution infrared camera (FLIR PM280, FLIR Systems).  
Infrared thermography images were taken from the upper half of the body to specifically 
visualize heat production from the BAT, as previously described (Czyzyk et al., 2012). 
 
Histological studies 
Tissues were extracted, fixed in 4% paraformaldehyde (Sigma), cut in 2-3 μm thick 
sections, and stained with hematoxylin/eosin.  Oil red staining of livers was performed on 
frozen sections fixed as before using 60% isopropanol saturated with oil red O dye (Sigma-
Aldrich) for 1 hour at room temperature.  Images were captured using an Olympus BX51 
microscope coupled to an Olympus DP70 digital camera.  Liver sections were analyzed by 
an independent pathologist to classify them according to steatotic grade (normal liver: 
stages 0-1 grade; non-alcoholic steatosis: stages 2-3; non-alcoholic steatohepatitis: stage 4).  
The size of white adipocytes was determined by measuring the cross-sectional area of at 
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least 150 randomly selected cells from four independent histological sections using 
Metamorph-Metaview software (Universal Imaging). Quantification of the number of 
brown adipocytes was done de visu by two individuals using four unlabeled images from 
BAT histological sections. 
 
Analysis of liver triglycerides 
Total lipids were extracted for 4 hours using an 8:1 mixture of chloroform and methanol 
from liver samples (50 mg) obtained from overnight fasted mice.  The lipophilic fraction 
was obtained, mixed with 1 N H2SO4 (Sigma), centrifuged for 10 min, and the amount of 
triglycerides determined enzymatically (Serum Triglyceride Determination Kit, Sigma). 
 
Plasma analyses 
Triglycerides and liver damage markers were determined using the SpotChem EZ Clinical 
Chemistry Analyzer (Menarini Diagnostics).  Insulin levels were measured using 
radioimmunoassays (RIA, Linco Research) according to manufacturer’s instructions.  
Plasma C-peptide levels were quantified before and upon the administration of glucose (2 
g/kg body mass) to animals using the Rat/mouse C-peptide ELISA kit (Millipore).  To 
analyze insulin clearance, mice were injected intraperitoneally with human insulin (1.5 
U/kg body mass) and the evolution of plasma levels measured at the indicated times using a 
human insulin ELISA kit (Millipore). All the above analyses were done using samples 
obtained from animals that were fasted for 18 hours before sample extraction.   Plasma 
catecholamine levels were determined as before (Sauzeau et al., 2006). The plasma 
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concentration of thyroid stimulating and thyroid hormones determined by 
radioimmunoassay at the National Hormone and Peptide Program of the National Institute 
of Diabetes and Digestive and Kidney Diseases. Plasma choline levels were determined 
using a Choline/Acetylcholine Assay Kit (Abcam) following the manufacturer’s 
instructions. 
 
Glucose and insulin tolerance tests 
These analyses were performed injecting intraperitoneally D-glucose (Sigma, 2 g/kg body 
weight, glucose tolerance tests) and insulin (Sigma, 0.75 U/kg body weight, insulin 
tolerance test) in mice that had been previously fasted for 18 hours.  Blood was collected 
from tail bleeds every 30 min over a 2 (insulin tolerance tests) to 3 hour (glucose tolerance 
tests) period and the amount of plasma glucose determined using a glucometer (Accucheck, 
Roche). Areas under the curve values were determined as described (Czyzyk et al., 2012). 
 
Western blot analyses 
To determine the activation of Akt by insulin in hepatocytes, overnight fasted mice were 
injected with either human insulin (0.3 U/kg body weight; Humulin, Eli Lilly) or control 
saline solution through the inferior vena cava.  Five minutes later animals were sacrificed, 
livers extracted and snap frozen.  Equal amounts of powdered tissue (20 mg) were 
homogenized and analyzed by Western blot as indicated (Castro-Castro et al., 2011). 
Rabbit polyclonal antibodies to Akt phosphorylated on residue Ser473 or Thr308 were 
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obtained from Cell Signaling.  Mouse monoclonal antibodies to α-tubulin were from 
Calbiochem.  All antibodies were used at a 1:1000 dilution. 
 
 
mRNA abundance determinations 
Total RNAs were extracted and quantitated as previously described (Citterio et al., 2012). 
Primers used for transcript quantitation included 5’-CGG TGT TGT GCG GTG TCT GTA 
GT-3’ (forward for mouse Ppargc1a), 5’-CGA TCA CCA TAT TCC AGG TCA AG-3’ 
(reverse for mouse Ppargc1a), 5’-CAG CTC AGA GCC GTG GTG A-3’ (forward for 
mouse Srbp1a), 5’-TTG ATA GAA GAC CGG TAG CGC-3’ (reverse for mouse Srbp1a), 
5’-TAG AGC ATA TCC CCC AGG TG-3’ (forward for mouse Srbp1c), 5’-GGT ACG 
GGC CAC AAG AAG TA-3’ (reverse for mouse Srbp1c), 5’-GAC CGT GGT GAT CCG 
CGG GG-3’ (forward for mouse Insig2), 5’-CTG AGG CTG TGC CGC AGC AT-3’ 
(reverse for mouse Insig2), 5’-TCC TCA GTC AGC TGC CCC GT-3’ (forward for mouse 
Ppara), 5’-TCC CGC GAG TAT GAC CCG GG-3’ (reverse for mouse Ppara), 5’-CAG 
CTC AGA GCC GTG GTG A-3’ (forward for mouse Srbf1), 5’-TTG ATA GAA GAC 
CGG TAG CGC-3’ (reverse for mouse Srbf1), 5’-CCA GGT CGT GGC TGG AGT CT-3’ 
(forward for mouse G6pc), 5’-TGT AGA TGC CCC GGA TGT G-3’ (reverse for mouse 
G6pc), 5’-CCA CAG CTG CTG CAG AAC AC-3’ (forward for mouse Pck1), 5’-GAA 
GGG TCG CAT GGC AAA-3’ (reverse for mouse Pck1), 5’-GGG CCC TTG TAA ACA 
ACA AA-3’ (forward for mouse Ucp1), 5’-GTC GGT CCT TCC TTG GTG TA-3’ 
(reverse for mouse Ucp1), 5’-GTC TGC CTC ATC AGG GTG TT-3’ (forward for mouse 
Menacho-Márquez et al. (2013) 
 18 
Ucp3), 5’-CCT GGT CCT TAC CAT GCA GT-3’ (reverse for mouse Ucp3), 5’-CCC ACA 
GAG AAA ATC CCA GGC TCA-3’ (forward for mouse Atf2), 5’-CGT TGG TAA AAC 
GCT GGC CAC A-3’ (reverse for mouse Atf2), 5’-ATC CGG GCC GCG AAC GAA AG-
3’ (forward for mouse Creb1), 5’-TGT GGC AAT CTG TGG CTG GGC-3’ (reverse for 
mouse Creb1), 5’-TGG GTG GTC AAC CCT CGG CA-3’ (forward for mouse Bmp7), 5’-
TGG AGC GAT TCT GGC TGC GC-3’ (reverse for mouse Bmp7), 5’-CCA CCA GCG 
AGG ACT TCA C-3’ (forward for mouse Pdrm16), 5’-GG GGA CTC TCG TAG CTC 
GAA-3’ (reverse for mouse Pdrm16), 5’-AAA GCA CGC TCG TCG CCA CA-3’ (forward 
for mouse Klf11), 5’-CAG AGG CCG GCA AGG GTT CG-3’ (reverse for mouse Klf11), 
5’-AGT CAC CAC AGG CTC GGC CA-3’ (forward for mouse Klf15), 5’-GGC ACA 
AGA GCA GGG GCT GG-3’ (reverse for mouse Klf15), 5’-CGG TTT CAG AAG TGC 
CTT GCT-3’ (forward for mouse Pparg), 5’-CGC CAA CAG CTT CTC CTT CTC-3’ 
(reverse for mouse Pparg), 5’-GGA GGT GGT GAT AGC CGG TAT-3’ (forward for 
mouse Fasn), 5’-TGG GTA ATC CAT AGA GCC CAG-3’ (reverse for mouse Fasn), 5’-
GTG TTT GAC AAC GGC AGC ATT-3’ (forward for mouse p36b4) and 5’-TTG ATG 
ATG GAG TGT GGC ACC-3’ (reverse for mouse p36b4). 
 
Pharmacological treatments 
SR59230A (Sigma) was dissolved in DMSO and diluted in sterile phosphate-buffered 
saline solution (2.5 mg/ml). 200 µl of either SR59230A or vehicle (3% DMSO in 
phosphate-buffered saline) solutions were injected subcutaneously during two consecutive 
days before mouse analysis.  Doxazosin (Pfizer Central Research) and propranolol (Sigma) 
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stocks were prepared in DMSO and diluted in the drinking water of animals to a final 
concentration of 30 and 25 mg/l, respectively.  Bicuculline (Sigma) was prepared in acid 
water and diluted (0.2 mg/ml) in sterile phosphate-buffered saline solution at the moment of 
the injection.  100 µl of that solution were injected intraperitoneally into mice 30 min 
before mouse euthanasia. Administration of bicuculline and noradrenaline in unconscious 
mice was done as described (Sauzeau et al., 2006). 
 
Determination of in vivo parasympathetic parameters 
In the case of gastric emptying, mice were fasted for 12 hours with free access to water and, 
subsequently, received food ad libitum for 1 hour. Food intake was then calculated by 
weighing the food left uneaten in the cage.  Mice were returned to the cages without food 
and water and euthanized by cervical dislocation after 1.5 hours.  The stomach was then 
exposed and its content weighed.  Gastric emptying was calculated according to the 
following formula: gastric emptying (%) = [1–(weight of food remaining in the 
stomach/weight of food intake)]×100.  We used Carmine red, a stain that cannot be 
absorbed from the lumen of the gut, to calculate gastrointestinal transit times (Kimball et 
al., 2005). To this end, 300 µl of a 6% Carmine red solution (Sigma-Aldrich) made in 0.5% 
methylcellulose (Sigma-Aldrich) were intragastrically administered by gavage using a 24 
gauge round-tip feeding needle (Fine Science Tools).  Fecal pellets were monitored since 
then at 10 min intervals to detect presence of the stain.  Total gastrointestinal transit time 
was considered as the interval between gavage procedure and the time in which carmine red 
was first observed in stools. 
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Blood pressure, heart rate, and breathing frequency determinations 
Blood pressure was recorded in either conscious or anesthetised animals as described 
elsewhere (Sauzeau et al., 2007; Sauzeau et al., 2010; Sauzeau et al., 2006).  The same 
references apply for the determination of the rest of cardiorespiratory parameters. 
 
Hepatic vagotomy 
The surgical procedure was performed as recently described (Imbernon et al., 2013). 
Briefly, 2.5 month-old wild type mice under ketamine-xylazine anesthesia were placed on 
their backs and a midline abdominal incision was made.  The liver was then carefully 
moved to the right exposing the esophagus.  Dorsal and ventral branches of the vagus nerve 
were exposed and dissected from the esophagus.  Each branch of the nerve was ligated with 
surgical suture at two points as distally as possible to prevent bleeding, and then cauterized 
in an area between the two sutures. Abdominal muscles and skin were then sutured with 
surgical silk. Sham surgeries were also performed, in which each trunk of the nerve was 
exposed but not tied up or cauterized.  Animals were analyzed in vivo in the post-surgery 
30th and 45th days and, eventually, euthanized when they were 4 month-old.  Effectiveness 
of the vagotomy was assessed by post-mortem stomach observation. Only mice showing an 
evident increase in stomach size after vagotomy (due to motoric dysfunction) were included 
in final analyses. 
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